FL H1281

Drug manufacturers are prohibited from denying, restricting, or interfering with the acquisition or delivery of 340B drugs to pharmacies contracted with 340B entities, and from interfering with pharmacies' rights to contract with 340B entities

Health insurers, pharmacy benefit managers, and third-party payors are prohibited from reimbursing 340B entities at lower rates than non-340B entities for the same drugs, or imposing different fees, clawbacks, dispensing fees, or network participation requirements based on 340B status

Insurers and PBMs cannot require 340B entities to identify drugs as 340B on claims, submit 340B pricing data, or reverse/resubmit claims solely due to 340B status, unless required by CMS or Florida Medicaid

Insurers and PBMs cannot exclude 340B entities from networks or interfere with patients' choice to receive drugs from 340B entities through restrictions or additional charges

Each violation constitutes a deceptive and unfair trade practice under the Florida Deceptive and Unfair Trade Practices Act, subject to investigative demands, remedies, and penalties; effective date is July 1, 2026